Related Experiment Videos
Angiotensin converting enzyme inhibition in heart failure: clinical trials and clinical practice
1Department of Medicine and Therapeutics, University of Leicester, UK. is11@le.ac.uk
Insights
Angiotensin converting enzyme (ACE) inhibitors are effective heart failure treatments but are underused. Educating healthcare professionals can improve ACE inhibitor prescription rates for better patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure (HF) is a prevalent, debilitating condition with effective pharmacological treatments.
- Angiotensin converting enzyme (ACE) inhibitors are a cornerstone therapy for HF, improving mortality and morbidity.
Purpose of the Study:
- To address the underutilization of ACE inhibitors in heart failure management.
- To highlight the gap between clinical trial evidence and routine practice regarding ACE inhibitor therapy.
Main Methods:
- Review of clinical trial data on ACE inhibitor efficacy and adverse effects.
- Analysis of factors influencing ACE inhibitor prescription rates in routine practice.
Main Results:
- ACE inhibitors significantly improve mortality and morbidity in heart failure patients.
- Physicians' perceptions of adverse effects (hypotension, renal impairment, cough) contribute to underutilization.
- Prescription rates correlate with physician expertise and motivation, not solely patient factors.
Conclusions:
- Despite proven benefits, ACE inhibitors are underprescribed in heart failure.
- Education for healthcare professionals is crucial to optimize ACE inhibitor use in heart failure.
- Addressing physician concerns and improving understanding of evidence can enhance therapy maximization.
Abstract:
Heart failure is a common and often debilitating condition, but one for which there exists a variety of effective pharmacological therapies. The angiotensin converting enzyme (ACE) inhibitors represent one of the mainstays of the treatment of heart failure. In spite of a wealth of evidence regarding the efficacy of these agents in improving mortality and morbidity in heart failure, they are often under-utilised. Failure to prescribe or to prematurely withdraw ACE inhibitor therapy often stems from physicians perceptions regarding the likelihood of unwanted effects, in particular hypotension, renal impairment and cough. The evidence from clinical trials is that these unwanted effects are relatively uncommon. In routine clinical practice the rate of prescription of ACE inhibitor therapy is related to the expertise and motivation of the physician. There is a need for education of all health care professionals involved in the care of patients with heart failure with regard to the maximisation of ACE inhibitor therapy in heart failure.